
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PCS12852
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Intact Therapeutics
Deal Size : $455.0 million
Deal Type : Licensing Agreement
Processa Pharmaceuticals Signs Binding Term Sheet agreement with Intact Therapeutics
Details : The agreement grants Intact the exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist for gastroparesis and other gastrointestinal motility disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2025
Lead Product(s) : PCS12852
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Intact Therapeutics
Deal Size : $455.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Processa Closes $5M Public Offering Under Nasdaq At-The-Market Rules
Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 30, 2025
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Processa Prices $5M Public Offering Under Nasdaq At-The-Market Rules
Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 27, 2025
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of NGC-Cap
Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Details : PCS6422 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 23, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Details : NGC-Iri is a prodrug of SN-38, the active molecule in irinotecan and Onivyde. It is currently being evaluated for the treatment of cancers.
Product Name : NGC-Iri
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces FDA Clearance of NGC-Cap Phase 2 Trial in Breast Cancer
Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Reports Positive Phase 1b Results with NGC-Cap in Cancer
Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $7.0 million
Deal Type : Public Offering
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Details : The net proceeds will be used to advance the development of PCS6422 (eniluracil) administered in combination with capecitabine, for the treatment of advanced, refractory gastrointestinal tract tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $7.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Completes Phase 1b Safety study of NGC-Cap Advanced Cancer, Recommends Phase 2
Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated in phase 1 clinical trials for gastrointestinal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
